JPWO2020204152A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020204152A5
JPWO2020204152A5 JP2021512315A JP2021512315A JPWO2020204152A5 JP WO2020204152 A5 JPWO2020204152 A5 JP WO2020204152A5 JP 2021512315 A JP2021512315 A JP 2021512315A JP 2021512315 A JP2021512315 A JP 2021512315A JP WO2020204152 A5 JPWO2020204152 A5 JP WO2020204152A5
Authority
JP
Japan
Prior art keywords
arm
specifically binds
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512315A
Other languages
English (en)
Japanese (ja)
Other versions
JP7405139B2 (ja
JPWO2020204152A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/015266 external-priority patent/WO2020204152A1/ja
Publication of JPWO2020204152A1 publication Critical patent/JPWO2020204152A1/ja
Publication of JPWO2020204152A5 publication Critical patent/JPWO2020204152A5/ja
Priority to JP2023198746A priority Critical patent/JP7688805B2/ja
Application granted granted Critical
Publication of JP7405139B2 publication Critical patent/JP7405139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512315A 2019-04-04 2020-04-03 二重特異性抗体 Active JP7405139B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023198746A JP7688805B2 (ja) 2019-04-04 2023-11-24 二重特異性抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019071840 2019-04-04
JP2019071840 2019-04-04
JP2020022256 2020-02-13
JP2020022256 2020-02-13
PCT/JP2020/015266 WO2020204152A1 (ja) 2019-04-04 2020-04-03 二重特異性抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023198746A Division JP7688805B2 (ja) 2019-04-04 2023-11-24 二重特異性抗体

Publications (3)

Publication Number Publication Date
JPWO2020204152A1 JPWO2020204152A1 (https=) 2020-10-08
JPWO2020204152A5 true JPWO2020204152A5 (https=) 2023-09-04
JP7405139B2 JP7405139B2 (ja) 2023-12-26

Family

ID=72669033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512315A Active JP7405139B2 (ja) 2019-04-04 2020-04-03 二重特異性抗体
JP2023198746A Active JP7688805B2 (ja) 2019-04-04 2023-11-24 二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023198746A Active JP7688805B2 (ja) 2019-04-04 2023-11-24 二重特異性抗体

Country Status (14)

Country Link
US (2) US12325746B2 (https=)
EP (1) EP3978015A4 (https=)
JP (2) JP7405139B2 (https=)
KR (1) KR20210149044A (https=)
CN (1) CN113660952B (https=)
AU (1) AU2020251578B2 (https=)
BR (1) BR112021019823A2 (https=)
CA (1) CA3136395A1 (https=)
IL (1) IL286918A (https=)
MX (1) MX2021012061A (https=)
PH (1) PH12021552501A1 (https=)
SG (1) SG11202110993QA (https=)
TW (1) TWI862565B (https=)
WO (1) WO2020204152A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI849895B (zh) * 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
WO2021006199A1 (ja) * 2019-07-05 2021-01-14 小野薬品工業株式会社 Pd-1/cd3二重特異性タンパク質による血液がん治療
US20230143066A1 (en) 2020-04-17 2023-05-11 Ono Pharmaceutical Co., Ltd. Method for removing color from drug substance of protein preparation
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A7 (fi) 1987-10-28 1989-04-29 Oncogen Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2111858A1 (en) 1991-07-15 1993-02-04 James S. Crowe Production of antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
NZ519012A (en) 2001-05-21 2003-10-31 Orgapack Gmbh Manually actuated strapping unit for wrapping a steel strap around a packaged item
WO2003011911A1 (fr) 2001-07-31 2003-02-13 Ono Pharmaceutical Co., Ltd. Substance specifique pour pd-1
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
JP2004072286A (ja) 2002-08-05 2004-03-04 Nippon Telegr & Teleph Corp <Ntt> 構造変化検出方法および通信網異常状態検出方法、並びに、その装置およびプログラム
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するFc変異体
CA2602663A1 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
PL3456190T3 (pl) * 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
EP2742953B1 (en) 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
EP3470431A1 (en) * 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
US20170096485A1 (en) * 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
CN106939050B (zh) * 2017-03-27 2019-05-10 顺昊细胞生物技术(天津)股份有限公司 抗pd1和cd19双特异性抗体及其应用
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
EP3693013A4 (en) * 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體

Similar Documents

Publication Publication Date Title
JPWO2020204152A5 (https=)
JP2025090743A5 (https=)
JP2020018311A5 (https=)
JP2017176174A5 (https=)
JP2018517431A5 (https=)
JP2020124209A5 (https=)
JP2009539348A5 (https=)
JP2010506596A5 (https=)
JP2020514301A5 (https=)
JP2009225799A5 (https=)
JP2007510664A5 (https=)
JP2020503885A5 (https=)
JP2017114866A5 (https=)
JP2019513784A5 (https=)
JP2020524000A5 (https=)
JP2018537415A5 (https=)
FI4249515T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2010535205A5 (https=)
JP2019528694A5 (https=)
JP2021502984A5 (https=)
JP2022111148A5 (https=)
JP2010509937A5 (https=)
JP2025118688A5 (https=)
JPWO2020102591A5 (https=)
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät